| Name | Title | Contact Details |
|---|---|---|
Chris Lawrence |
Chief Information Officer, Chief Information Security Officer | Profile |
Throughout our 100 plus year history, Hartig Drug has played a key role in progressive retail practices. Did you know that Hartig Drug opened the first self-service drug store in Iowa and was one of the first pharmacies to employ female pharmacists and store managers? The principles upon which A.J. Hartig founded the company, offering the best product selection and providing fanatical service to his customers, are the corner stone of our company culture today. Hartig Drug has expanded its product offerings in retail and pharmacy and has grown via the addition of many stores throughout the years. Our drug stores and pharmacies are located in communities in Northeast Iowa, Northwest Illinois, and Southwest Wisconsin. Hartig Drug operates retail stores, long-term care pharmacies, and Finley Hartig Homecare, a durable medical equipment company. Additionally, we provide pharmacy services to and for several community critical access hospitals and operate MedOne Healthcare, a pharmacy benefit management company that offers customized prescription benefit plans to businesses, prescription discount programs, prescription mail order service and specialty pharmacy services. Hartig Drug remains active in the communities in which we serve. Our employees, live, work and play in the communities in which we operate. This connection to the community is what drives us every day to provide the best possible service and products to our patients and customers. They are our neighbors. At Hartig Drug, we cherish the faith and trust patients and customers have placed in our brand and the way the Hartig name has become synonymous with value, caring associates and a wide selection of quality merchandise.
Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
Corepharma LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmaprint Inc is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.